Inside BENEO’s new pulse plant: pioneering sustainable protein from faba beans
To build India’s first outcome-driven nutraceuticals brand
ZeroHarm Sciences, India’s first nano-formulated plant-based nutraceutical brand, announced the successful closure of a Rs 65 crore funding round. Kotak Alternate Asset Managers, through its Kotak Life Sciences Fund I, has invested Rs 40 crore, while Alkemi Growth Capital, a healthcare and consumer wellness-focused venture fund, has invested Rs 25 crore. Cipher-Plexus was the exclusive financial advisor to the transaction.
The capital will be primarily deployed to build India’s first “Trust over Promise” health platform — a model where supplement efficacy is demonstrated through measurable consumer health outcomes, not unverifiable marketing claims. Alongside this, ZeroHarm will invest in national brand building, international expansion across the US, the UK, and the Middle East, and scaling its vertically integrated R&D and manufacturing ecosystem.
Ashish Ranjan, Director, Kotak Alts, said, “The Indian nutraceuticals market is supported by favourable macroeconomic, demand, and supply-side drivers. It remains in the early stages of adoption and is poised for exponential growth. ZeroHarm is redefining preventive care and wellness by seamlessly integrating the timeless wisdom of Ayurveda with advanced technology, delivering solutions that are safe, effective, and scalable. Their fully integrated model — from extraction to formulation to manufacturing — is a key differentiator that sets them apart in this space.”
Alka Goel, Founder and Managing Partner, Alkemi Growth Capital, said, “ZeroHarm represents exactly the kind of company Alkemi was built to support — a science-first, consumer-centric health brand that is solving real problems with proprietary technology and deep domain expertise. Sachin and the team have built a rare combination of farm-to-tablet integration, nano-formulation IP, and a strong D2C engine. We are excited to partner with them as they scale this platform nationally and globally.”
Sachin Darbarwar, Co-Founder and CEO, ZeroHarm Sciences, said, “India’s supplement market has a trust deficit — consumers are asked to believe claims they can never verify. This investment allows us to change that equation fundamentally. We are building India’s first ‘Trust over Promise’ platform, where every customer can see measurable health outcomes through before-and-after diagnostic testing. That’s not marketing — that’s medicine-grade accountability applied to wellness.”